BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25168574)

  • 1. Pathological factors associated with survival benefit from adjuvant chemotherapy (ACT): a population-based study of bladder cancer.
    Booth CM; Siemens DR; Wei X; Peng Y; Berman DM; Mackillop WJ
    BJU Int; 2015 Sep; 116(3):373-81. PubMed ID: 25168574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study.
    Booth CM; Siemens DR; Li G; Peng Y; Tannock IF; Kong W; Berman DM; Mackillop WJ
    Cancer; 2014 Jun; 120(11):1630-8. PubMed ID: 24733278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radical cystectomy and adjuvant chemotherapy for bladder cancer in the elderly: a population-based study.
    Leveridge MJ; Siemens DR; Mackillop WJ; Peng Y; Tannock IF; Berman DM; Booth CM
    Urology; 2015 Apr; 85(4):791-8. PubMed ID: 25661830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy is possibly beneficial for locally advanced or node-positive bladder cancer.
    Kanatani A; Nakagawa T; Kawai T; Naito A; Sato Y; Yoshida K; Nozaki K; Nagata M; Yamada Y; Azuma T; Suzuki M; Fujimura T; Fukuhara H; Nishimatsu H; Kume H; Igawa Y; Homma Y
    Clin Genitourin Cancer; 2015 Apr; 13(2):e107-12. PubMed ID: 25456839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a.
    May M; Bastian PJ; Brookman-May S; Fritsche HM; Tilki D; Otto W; Bolenz C; Gilfrich C; Trojan L; Herrmann E; Moritz R; Tiemann A; Müller SC; Ellinger J; Buchner A; Stief CG; Wieland WF; Höfner T; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Nuhn P; Burger M
    Urol Oncol; 2013 Oct; 31(7):1141-7. PubMed ID: 22056404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
    Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
    Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of squamous histology in bladder cancer: a population-based study.
    Izard JP; Siemens DR; Mackillop WJ; Wei X; Leveridge MJ; Berman DM; Peng Y; Booth CM
    Urol Oncol; 2015 Oct; 33(10):425.e7-13. PubMed ID: 26199176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2.
    Aziz A; Lessard A; Moore K; Hovington H; Latulippe E; Larue H; Fradet Y; Lacombe L
    BJU Int; 2011 Aug; 108(4):531-7. PubMed ID: 21166751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: a systematic review and meta-analysis.
    Zhang L; Wu B; Zha Z; Qu W; Zhao H; Yuan J
    BMC Cancer; 2019 Jul; 19(1):716. PubMed ID: 31324162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes.
    Ma B; Li H; Zhang C; Yang K; Qiao B; Zhang Z; Xu Y
    Eur J Surg Oncol; 2013 Oct; 39(10):1150-6. PubMed ID: 23721764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis.
    Fajkovic H; Cha EK; Jeldres C; Robinson BD; Rink M; Xylinas E; Chromecki TF; Breinl E; Svatek RS; Donner G; Tagawa ST; Tilki D; Bastian PJ; Karakiewicz PI; Volkmer BG; Novara G; Joual A; Faison T; Sonpavde G; Daneshmand S; Lotan Y; Scherr DS; Shariat SF
    Eur Urol; 2013 Nov; 64(5):837-45. PubMed ID: 22877503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Processes of care and the impact of surgical volumes on cancer-specific survival: a population-based study in bladder cancer.
    Siemens DR; Mackillop WJ; Peng Y; Berman D; Elharram A; Rhee J; Booth CM
    Urology; 2014 Nov; 84(5):1049-57. PubMed ID: 25443899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between comorbidity, and overall survival and bladder cancer specific survival after radical cystectomy: results from the Alberta Urology Institute Radical Cystectomy database.
    Fairey AS; Jacobsen NE; Chetner MP; Mador DR; Metcalfe JB; Moore RB; Rourke KF; Todd GT; Venner PM; Voaklander DC; Estey EP
    J Urol; 2009 Jul; 182(1):85-92; discussion 93. PubMed ID: 19447413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of radical cystectomy with extended lymphadenectomy alone in patients with lymph node-positive bladder cancer who are unfit for or who decline adjuvant chemotherapy.
    Zehnder P; Studer UE; Daneshmand S; Birkhäuser FD; Skinner EC; Roth B; Miranda G; Burkhard FC; Cai J; Skinner DG; Thalmann GN; Gill IS
    BJU Int; 2014 Apr; 113(4):554-60. PubMed ID: 24131453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of adjuvant chemotherapy in locally advanced bladder cancer.
    Haque W; Lewis GD; Verma V; Darcourt JG; Butler EB; Teh BS
    Acta Oncol; 2018 Apr; 57(4):509-515. PubMed ID: 29226744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
    Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
    BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of adjuvant chemotherapy in transitional cell carcinoma of the urinary bladder with lymph node involvement and/or lymphovascular invasion treated by radical cystectomy.
    Park J; Park S; Song C; Doo C; Cho YM; Ahn H; Kim CS
    Urology; 2007 Aug; 70(2):257-62. PubMed ID: 17826485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy.
    Lotan Y; Gupta A; Shariat SF; Palapattu GS; Vazina A; Karakiewicz PI; Bastian PJ; Rogers CG; Amiel G; Perotte P; Schoenberg MP; Lerner SP; Sagalowsky AI
    J Clin Oncol; 2005 Sep; 23(27):6533-9. PubMed ID: 16116151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence of lymphovascular invasion in radical cystectomy specimens from patients with urothelial carcinoma portends a poor clinical prognosis.
    Canter D; Guzzo T; Resnick M; Magerfleisch L; Sonnad S; Bergey M; Tomazewski J; Vaughn D; Van Arsdalen K; Malkowicz B
    BJU Int; 2008 Sep; 102(8):952-7. PubMed ID: 18485042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of patients with pathological tumor stage T3 urothelial carcinoma of the bladder following radical cystectomy in a single-center series with 116 patients.
    Breyer J; Denzinger S; Otto W; Bründl J; Gierth M; Fritsche HM; Rößler W; Wieland WF; Giedl C; Hofstädter F; Rubenwolf P; Burger M; Aziz A
    Urol Int; 2014; 93(3):311-9. PubMed ID: 25196313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.